Lexicon to Host Conference Call and Webcast to Review Top-Line Phase 2 Results From Diabetes Trial
January 26 2010 - 6:15PM
PR Newswire (US)
THE WOODLANDS, Texas, Jan. 26 /PRNewswire-FirstCall/ -- Lexicon
Pharmaceuticals, Inc. (NASDAQ:LXRX) will hold a conference call on
Thursday, January 28, 2010 at 11:30 am Eastern Time to discuss its
recent top-line Phase 2 clinical results with LX4211, Lexicon's
once-per-day, orally-delivered, small molecule drug candidate for
the treatment of type 2 diabetes mellitus. The dial-in number for
the conference call is 888-220-1244 (within the US/Canada) or
706-679-5615 (international). The conference ID for all callers is
53373071. Investors can access a live webcast of the call at
http://www.lexpharma.com/. An archived version of the webcast will
be available on the website. About Lexicon Lexicon is a
biopharmaceutical company focused on discovering and developing
breakthrough treatments for human disease. Lexicon currently has
five drug candidates in development for diabetes, autoimmune
disease, carcinoid syndrome, glaucoma and irritable bowel syndrome,
all of which were discovered by Lexicon's research team. Lexicon
has used its proprietary gene knockout technology to identify more
than 100 promising drug targets. Lexicon has focused drug discovery
efforts on these biologically-validated targets to create its
extensive pipeline of clinical and preclinical programs. For
additional information about Lexicon and its programs, please visit
http://www.lexpharma.com/. Safe Harbor Statement This press release
contains "forward-looking statements," including statements
relating to Lexicon's growth and future operating results,
discovery and development of products, strategic alliances and
intellectual property, as well as other matters that are not
historical facts or information. All forward-looking statements are
based on management's current assumptions and expectations and
involve risks, uncertainties and other important factors that may
cause Lexicon's actual results to be materially different from any
future results expressed or implied by such forward-looking
statements. Information identifying such important factors is
contained under "Factors Affecting Forward-Looking Statements" and
"Risk Factors" in Lexicon's annual report on Form 10-K for the year
ended December 31, 2008, as filed with the Securities and Exchange
Commission. Lexicon undertakes no obligation to update or revise
any such forward-looking statements, whether as a result of new
information, future events or otherwise. DATASOURCE: Lexicon
Pharmaceuticals, Inc. CONTACT: D. Wade Walke, Ph.D., Director,
Corporate Communications of Lexicon Pharmaceuticals, Inc.,
+1-281-863-3046, Web Site: http://www.lexpharma.com/
Copyright
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Jul 2023 to Jul 2024